#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky

Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like heart attacks and strokes. If the ...